TGFBI and cancer: With βigH3 expression being related to poor patient outcome across several types of cancer and expected relation between release of cβigH3 and ECM degradation, it could be speculated that increased cβigH3 levels would reflect degradation of tumor-promoting ECM, thus making cβigH3 a potential pharmacodynamic biomarker for anti-fibrotic treatments.